A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
This is an open-label, randomized, controlled, two-part study to evaluate the safety and efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.
Ovarian Cancer
DRUG: SHR-1921|DRUG: carboplatin|DRUG: carboplatin|DRUG: platinum-based doublet chemotherapy
Objective Response Rate Assessed by Investigator According to RECIST v1.1, Screening up to study completion, an average of 1 year
Duration of Response (DoR) Assessed by Investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Disease Control Rate (DCR) Assessed by Investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Progression-Free Survival (PFS) Assessed by Investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Overall Survival (OS), Screening up to study completion, an average of 1 year|CA-125 Response assessed by the Gynecologic Cancer Intergroup (GCIG) criteria, Screening up to study completion, an average of 1 year
This is an open-label, randomized, controlled, two-part study to evaluate the safety and efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.